GERON CORP (GERN) Fundamental Analysis & Valuation

NASDAQ:GERN • US3741631036

Current stock price

1.66 USD
0 (0%)
At close:
1.65 USD
-0.01 (-0.6%)
After Hours:

This GERN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. GERN Profitability Analysis

1.1 Basic Checks

  • In the past year GERN has reported negative net income.
  • GERN had a negative operating cash flow in the past year.
  • GERN had negative earnings in each of the past 5 years.
  • GERN had a negative operating cash flow in each of the past 5 years.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • GERN's Return On Assets of -14.64% is fine compared to the rest of the industry. GERN outperforms 78.34% of its industry peers.
  • GERN has a better Return On Equity (-36.97%) than 69.63% of its industry peers.
Industry RankSector Rank
ROA -14.64%
ROE -36.97%
ROIC N/A
ROA(3y)-30.25%
ROA(5y)-43.32%
ROE(3y)-57.83%
ROE(5y)-88.55%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • GERN has a Gross Margin of 97.42%. This is amongst the best in the industry. GERN outperforms 97.10% of its industry peers.
  • GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. GERN Health Analysis

2.1 Basic Checks

  • GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GERN has been increased compared to 1 year ago.
  • Compared to 5 years ago, GERN has more shares outstanding
  • The debt/assets ratio for GERN is higher compared to a year ago.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -1.82, we must say that GERN is in the distress zone and has some risk of bankruptcy.
  • GERN has a Altman-Z score (-1.82) which is in line with its industry peers.
  • GERN has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.03, GERN is not doing good in the industry: 76.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -1.82
ROIC/WACCN/A
WACC8.98%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that GERN has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.66, GERN perfoms like the industry average, outperforming 52.42% of the companies in the same industry.
  • A Quick Ratio of 3.62 indicates that GERN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.62, GERN is in line with its industry, outperforming 46.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.62
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GERN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 62.96% over the past year.
  • GERN shows a strong growth in Revenue. In the last year, the Revenue has grown by 138.83%.
  • Measured over the past years, GERN shows a very strong growth in Revenue. The Revenue has been growing by 274.39% on average per year.
EPS 1Y (TTM)62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)138.83%
Revenue growth 3Y574.21%
Revenue growth 5Y274.39%
Sales Q2Q%1%

3.2 Future

  • GERN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.25% yearly.
  • Based on estimates for the next years, GERN will show a very strong growth in Revenue. The Revenue will grow by 37.44% on average per year.
EPS Next Y55.8%
EPS Next 2Y50.17%
EPS Next 3Y33.08%
EPS Next 5Y51.25%
Revenue Next Year22.81%
Revenue Next 2Y32.87%
Revenue Next 3Y36.84%
Revenue Next 5Y37.44%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

1

4. GERN Valuation Analysis

4.1 Price/Earnings Ratio

  • GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GERN's earnings are expected to grow with 33.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.17%
EPS Next 3Y33.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GERN Dividend Analysis

5.1 Amount

  • No dividends for GERN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GERN Fundamentals: All Metrics, Ratios and Statistics

GERON CORP

NASDAQ:GERN (4/2/2026, 8:00:01 PM)

After market: 1.65 -0.01 (-0.6%)

1.66

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners75.89%
Inst Owner Change0%
Ins Owners0.07%
Ins Owner Change3.82%
Market Cap1.06B
Revenue(TTM)183.88M
Net Income(TTM)-83.50M
Analysts78.46
Price Target3.32 (100%)
Short Float %9.96%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.48%
Min EPS beat(2)10.87%
Max EPS beat(2)38.09%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)10.87%
Max EPS beat(4)38.09%
EPS beat(8)8
Avg EPS beat(8)23.65%
EPS beat(12)11
Avg EPS beat(12)20.91%
EPS beat(16)14
Avg EPS beat(16)19.35%
Revenue beat(2)0
Avg Revenue beat(2)-9.54%
Min Revenue beat(2)-12.44%
Max Revenue beat(2)-6.64%
Revenue beat(4)1
Avg Revenue beat(4)-8.99%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)2.61%
Revenue beat(8)5
Avg Revenue beat(8)166.58%
Revenue beat(12)6
Avg Revenue beat(12)108.96%
Revenue beat(16)8
Avg Revenue beat(16)92.63%
PT rev (1m)2.63%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.19%
EPS NY rev (1m)0%
EPS NY rev (3m)31.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.78
P/FCF N/A
P/OCF N/A
P/B 4.71
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.29
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.64%
ROE -36.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.42%
FCFM N/A
ROA(3y)-30.25%
ROA(5y)-43.32%
ROE(3y)-57.83%
ROE(5y)-88.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.34%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.66
Quick Ratio 3.62
Altman-Z -1.82
F-Score2
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)107.55%
Cap/Depr(5y)113.28%
Cap/Sales(3y)117.04%
Cap/Sales(5y)87.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y55.8%
EPS Next 2Y50.17%
EPS Next 3Y33.08%
EPS Next 5Y51.25%
Revenue 1Y (TTM)138.83%
Revenue growth 3Y574.21%
Revenue growth 5Y274.39%
Sales Q2Q%1%
Revenue Next Year22.81%
Revenue Next 2Y32.87%
Revenue Next 3Y36.84%
Revenue Next 5Y37.44%
EBIT growth 1Y70.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.47%
EBIT Next 3Y19.91%
EBIT Next 5YN/A
FCF growth 1Y49.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.21%
OCF growth 3YN/A
OCF growth 5YN/A

GERON CORP / GERN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GERON CORP?

ChartMill assigns a fundamental rating of 3 / 10 to GERN.


Can you provide the valuation status for GERON CORP?

ChartMill assigns a valuation rating of 1 / 10 to GERON CORP (GERN). This can be considered as Overvalued.


What is the profitability of GERN stock?

GERON CORP (GERN) has a profitability rating of 2 / 10.


Can you provide the financial health for GERN stock?

The financial health rating of GERON CORP (GERN) is 3 / 10.